<DOC>
	<DOCNO>NCT00124956</DOCNO>
	<brief_summary>This protocol design obtain detailed information impact body composition pharmacokinetic behavior doxorubicin single intravenous dose child 21 year age younger . There efficacy component . Approximately 9 child enrol Children 's Hospital Boston . The information gain study could important develop dose strategy doxorubicin obese patient population .</brief_summary>
	<brief_title>Doxorubicin Pharmacokinetic ( PK ) Study</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Eligible patient &gt; 1 â‰¤ 21 year old . All patient must receive chemotherapy include doxorubicin administer infusion duration &lt; 24 hour , either 1day 2day schedule . This include bolus short infusion schedule . All patient parents/legal guardian provide inform consent/assent ( required law ) indicate awareness investigational nature risk study accord inform consent process . Women know pregnant lactating Patients significant uncontrolled systemic illness Serum glutamic oxaloacetic transaminase ( SGOT/AST ) , serum glutamic pyruvate transaminase ( SGPT/ALT ) &gt; 3 time upper limit normal test within 14 day prior infusion Bilirubin &gt; upper limit normal test within 14 day prior infusion Patients whose dose doxorubicin base ideal body weight Patients weigh &lt; 12 kilograms time screen</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>